Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.

@article{Mazires2013LungCT,
  title={Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.},
  author={J. Mazi{\`e}res and S. Peters and B. Lepage and A. Cortot and F. Barlesi and M. Beau-Faller and B. Besse and H. Blons and A. Mansuet‐Lupo and T. Urban and D. Moro-Sibilot and {\'E}. Dansin and C. Chouaid and M. Wislez and J. Diebold and E. Felip and I. Rouquette and J. Milia and O. Gautschi},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2013},
  volume={31 16},
  pages={
          1997-2003
        }
}
  • J. Mazières, S. Peters, +16 authors O. Gautschi
  • Published 2013
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • PURPOSE HER2 mutations are identified in approximately 2%of non-small-cell lung cancers (NSCLC). There are few data available that describe the clinical course of patients with HER2-mutated NSCLC. PATIENTS AND METHODS We retrospectively identified 65 NSCLC, diagnosed with a HER2 in-frame insertion in exon 20. We collected clinicopathologic characteristics, patients' outcomes, and treatments. RESULTS HER2 mutation was identified in 65 (1.7%) of 3,800 patients tested and was almost an… CONTINUE READING
    426 Citations

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    The purpose of this study is to investigate the control of disease in pretreated patients with advanced non small cell lung cancer (NSCLC) harbouring HER2 exon 20 mutations as well as… Expand
    ConditionsNSCLC
    InterventionDrug
    Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea
    • Kangkook Lee, H. Jung, +4 authors M. Ahn
    • Medicine
    • Cancer research and treatment : official journal of Korean Cancer Association
    • 2019
    • 2
    • PDF
    Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
    • 148
    Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma
    • 19
    • PDF
    Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.
    • 27
    • Highly Influenced

    References

    SHOWING 1-10 OF 27 REFERENCES
    Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains
    • C. Li, Y. Sun, +10 authors Haiquan Chen
    • Biology, Medicine
    • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
    • 2012
    • 73
    Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers.
    • 117
    Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas
    • 271
    • PDF
    HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin.
    • 133
    • PDF
    Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
    • 597
    • PDF
    Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features
    • 158
    HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer.
    • 146
    The Role of Human Epidermal Growth Factor Receptor 2 as a Prognostic Factor in Lung Cancer: A Meta-Analysis of Published Data
    • L. Liu, X. Shao, +6 authors Y. Shu
    • Medicine
    • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
    • 2010
    • 82